Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29020366 | 0.97 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Carbon Dioxide SCHEMBL7040864 | 0.85 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Carbimide SCHEMBL4053621 | 0.85 | CHRM2 (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Carbimide SCHEMBL28645014 | 0.81 | — | — | |
| SCHEMBL28265390 | 0.79 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28187686 | 0.79 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Propane SCHEMBL25170512 | 0.76 | — | — | |
| Propane SCHEMBL1304230 | 0.76 | — | — | |
| Propane SCHEMBL11799721 | 0.76 | — | — | |
| Propane SCHEMBL111122 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1112303-A2 | CURING OF RESINS | Chemcolloids Limited (GB) | 2001-07-04 | — | — | EP | claimed |
| WO-2000015694-A2 | CURING OF RESINS | CHEMCOLLOIDS LIMITED (GB) | 2000-03-23 | — | — | WO | claimed |
| US-10391070-B2 | Compositions and methods for treating neurological diseases or injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-07-05 | — | — | US | disclosed |
| US-9861596-B2 | Compositions and methods for treating neurological diseases or injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-01-09 | — | — | US | disclosed |
| CN-106146484-A | Quinazoline derivant is as RAF kinase modulator and their method and purposes | 埃姆比特生物科学公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20150320702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2015-11-12 | — | — | US | disclosed |
| WO-2014074976-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-1112303-A2 | CURING OF RESINS | Chemcolloids Limited (GB) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015694-A2 | CURING OF RESINS | CHEMCOLLOIDS LIMITED (GB) | 2000-03-23 | — | — | WO | disclosed |
| US-5481035-A | REACTING AMMONIUM ISOCYANATE WITH AMINES TO PRODUCE UREAS | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1996-01-02 | — | — | US | disclosed |
| EP-0416236-B1 | Process for the isolation isocyanic acid from a gaseous mixture of isocyanic acid and ammonia | CHEMIE LINZ GMBH (AT) | 1995-11-08 | — | — | EP | disclosed |
| EP-0410169-B1 | Process for the preparation of asymmetrically substituted ureas, carbamates, thiocarbamates and substituted isocyanates | CHEMIE LINZ GMBH (AT) | 1994-12-14 | — | — | EP | disclosed |
| US-5248755-A | With adduct of isocyanic acid and tertiary amine | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1993-09-28 | — | — | US | disclosed |
| US-5223635-A | Preparation of organic compounds using as a reactant an adduct of isocyanic acid and a tertiary amine or an ether | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1993-06-29 | — | — | US | disclosed |
| US-5091553-A | PROCESS FOR THE PREPARATION OF SUBSTITUTED ISOCYANATES | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1992-02-25 | — | — | US | disclosed |
| EP-0468308-A2 | Process for the preparation of beta-fluorinated alcohols | BAYER AG (DE) | 1992-01-29 | — | — | EP | disclosed |
| US-5078980-A | Forming an adduct with an ether or tertiary amine, chemical intermediates for ureas, thiocarbamates and isocyanates | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1992-01-07 | — | — | US | disclosed |
| EP-0416236-A2 | Process for the isolation isocyanic acid from a gaseous mixture of isocyanic acid and ammonia | Chemie Linz GmbH (AT) | 1991-03-13 | — | — | EP | disclosed |
| EP-0410169-A2 | Process for the preparation of asymmetrically substituted ureas, carbamates, thiocarbamates and substituted isocyanates | Chemie Linz GmbH (AT) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391070-B2 | Compositions and methods for treating neurological diseases or injury | PROC, GLS, NLN | CHRM2 2099/4885CHRM4 3210/4885CHRM5 2753/4885 |
| US-20150320702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | PROC, GLS, NLN | CHRM2 2099/4885CHRM4 3210/4885CHRM5 2753/4885 |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | PROC, GLS, NLN | CHRM2 2099/4885CHRM4 3210/4885CHRM5 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.